Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Starfield Direct reveals New Atlantis is Bethesda's 'biggest city' yet, in more ways than one
Abkhazia media guide
'I don't agree with it': xQc slams Call of Duty's decision to remove Nickmercs for anti-LGBTQ remarks
MTG Ob Nixilis, Captive Kingpin Combo Explained
EA Sports FC 24 Ratings Leak: The 10 Best Players Overall
Detroit of Asia Targets Battery Makers to Stay Ahead in EV Race
These Stocks Are Moving the Most Today: Workday, Las Vegas Sands, Fluence Energy, NetApp, Jabil, and More
US judge rejects challenges to Apple's $50 million keyboard settlement